78.04
price up icon3.24%   2.45
after-market Handel nachbörslich: 80.00 1.96 +2.51%
loading
Schlusskurs vom Vortag:
$75.59
Offen:
$75.77
24-Stunden-Volumen:
1.62M
Relative Volume:
0.87
Marktkapitalisierung:
$15.11B
Einnahmen:
$4.41B
Nettoeinkommen (Verlust:
$21.27M
KGV:
243.88
EPS:
0.32
Netto-Cashflow:
$288.81M
1W Leistung:
+11.23%
1M Leistung:
+14.01%
6M Leistung:
+5.29%
1J Leistung:
+21.05%
1-Tages-Spanne:
Value
$75.48
$78.25
1-Wochen-Bereich:
Value
$71.00
$78.77
52-Wochen-Spanne:
Value
$53.56
$83.95

Incyte Corp Stock (INCY) Company Profile

Name
Firmenname
Incyte Corp
Name
Telefon
(302) 498-6700
Name
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Mitarbeiter
2,617
Name
Twitter
@Incyte
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
INCY's Discussions on Twitter

Vergleichen Sie INCY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INCY
Incyte Corp
78.04 14.76B 4.41B 21.27M 288.81M 0.32
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 118.67B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.54 59.23B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
419.56 52.67B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
690.32 41.24B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
304.30 32.36B 3.81B -644.79M -669.77M -6.24

Incyte Corp Stock (INCY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-01 Eingeleitet Barclays Overweight
2025-06-16 Hochstufung Stifel Hold → Buy
2025-03-18 Herabstufung Guggenheim Buy → Neutral
2025-03-18 Herabstufung William Blair Outperform → Mkt Perform
2024-12-17 Eingeleitet UBS Neutral
2024-10-29 Hochstufung BofA Securities Neutral → Buy
2024-10-01 Eingeleitet Wolfe Research Outperform
2024-09-18 Herabstufung Truist Buy → Hold
2024-07-02 Herabstufung BMO Capital Markets Market Perform → Underperform
2024-05-23 Eingeleitet Deutsche Bank Hold
2024-04-23 Eingeleitet Cantor Fitzgerald Neutral
2024-02-23 Eingeleitet Jefferies Buy
2024-02-14 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 Hochstufung Leerink Partners Market Perform → Outperform
2023-12-04 Hochstufung Guggenheim Neutral → Buy
2023-11-21 Herabstufung Goldman Buy → Neutral
2023-07-25 Eingeleitet Citigroup Buy
2023-05-04 Herabstufung BofA Securities Buy → Neutral
2023-04-10 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-03-24 Hochstufung SVB Securities Underperform → Market Perform
2023-01-31 Eingeleitet Piper Sandler Overweight
2022-08-03 Herabstufung Evercore ISI Outperform → In-line
2022-08-03 Herabstufung Guggenheim Buy → Neutral
2022-07-28 Eingeleitet Wells Fargo Equal Weight
2022-02-09 Herabstufung SVB Leerink Mkt Perform → Underperform
2022-01-18 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-19 Eingeleitet BMO Capital Markets Market Perform
2021-07-20 Hochstufung The Benchmark Company Hold → Buy
2021-02-10 Herabstufung SVB Leerink Mkt Perform → Underperform
2021-01-07 Eingeleitet Truist Buy
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-06-16 Eingeleitet The Benchmark Company Hold
2020-05-06 Herabstufung JP Morgan Overweight → Neutral
2020-04-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-04-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-24 Fortgesetzt William Blair Outperform
2020-03-13 Hochstufung BofA/Merrill Neutral → Buy
2020-02-04 Fortgesetzt BofA/Merrill Neutral
2020-01-03 Bestätigt BMO Capital Markets Market Perform
2020-01-03 Herabstufung Mizuho Buy → Neutral
2020-01-02 Herabstufung Guggenheim Buy → Neutral
2019-10-03 Eingeleitet Mizuho Buy
2019-09-12 Eingeleitet BMO Capital Markets Market Perform
2019-09-05 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 Fortgesetzt Morgan Stanley Equal-Weight
2019-09-05 Hochstufung Oppenheimer Perform → Outperform
2019-05-21 Eingeleitet Credit Suisse Neutral
2019-05-03 Herabstufung Barclays Overweight → Equal Weight
2019-04-11 Eingeleitet Stifel Hold
2019-04-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-01-24 Hochstufung William Blair Mkt Perform → Outperform
Alle ansehen

Incyte Corp Aktie (INCY) Neueste Nachrichten

pulisher
04:47 AM

Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America - The Manila Times

04:47 AM
pulisher
Aug 03, 2025

Incyte's (INCY) "Neutral" Rating Reiterated at UBS Group - MarketBeat

Aug 03, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Incyte Corporation stockUnlock powerful investment tools for free - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Incyte Corporation stock price move sharplyBuild wealth faster with expert stock picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 01, 2025

Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer - Stocktwits

Aug 01, 2025
pulisher
Aug 01, 2025

Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News - GuruFocus

Aug 01, 2025
pulisher
Aug 01, 2025

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Benzinga

Aug 01, 2025
pulisher
Aug 01, 2025

Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada

Aug 01, 2025
pulisher
Aug 01, 2025

Barclays initiates coverage on Incyte stock with Overweight rating - Investing.com

Aug 01, 2025
pulisher
Aug 01, 2025

Incyte's Stock Price Target Raised by RBC Capital to $72.00 - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus

Aug 01, 2025
pulisher
Jul 30, 2025

Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - Jammu Links News

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte stock price target raised to $72 from $68 at RBC Capital By Investing.com - Investing.com South Africa

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte stock price target raised to $60 from $52 at BMO Capital By Investing.com - Investing.com South Africa

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 30, 2025
pulisher
Jul 30, 2025

Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte: Q2 Earnings Snapshot - Huron Daily Tribune

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance

Jul 30, 2025
pulisher
Jul 30, 2025

Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Jul 30, 2025
pulisher
Jul 29, 2025

Incyte Raises Its Outlook After Beating Expectations On Jakafi Sales - Finimize

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte rises on results beat, lifted Jakafi guidance - MSN

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte stock price target raised to $79 by Truist on strong Jakafi sales - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 By Investing.com - Investing.com South Africa

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte’s Blood Cancer Drug Sales Forecast Gets A Lift - Finimize

Jul 29, 2025
pulisher
Jul 29, 2025

Celestica, Corning, And Incyte Impress With Upbeat Quarterly Results - Finimize

Jul 29, 2025
pulisher
Jul 29, 2025

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte lifts annual sales forecast for blood cancer drug after solid quarter - whbl.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga

Jul 29, 2025
pulisher
Jul 29, 2025

Earnings call transcript: Incyte Q2 2025 reveals revenue miss, stock gains - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say - Nasdaq

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Q2 Results Top Estimates - Nasdaq

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Corp. Achieves Strong Financial Performance in Q2News and Statistics - IndexBox

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Q2 2025 slides: revenue up 16%, raises guidance on strong product performance - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates - Nasdaq

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte misses Q2 earnings estimates, raises Jakafi guidance By Investing.com - Investing.com Canada

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte misses Q2 earnings estimates, raises Jakafi guidance - Investing.com

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Corp Q2 2025 Earnings: EPS of $2.04 and Revenue of $1.216 Billion Surpass Estimates - GuruFocus

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Reports 2025 Second Quarter Financial Results - TradingView

Jul 29, 2025
pulisher
Jul 29, 2025

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Yahoo Finance

Jul 29, 2025

Finanzdaten der Incyte Corp-Aktie (INCY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$37.88
price up icon 2.07%
$111.24
price up icon 2.35%
$29.32
price up icon 8.31%
$110.03
price up icon 2.51%
biotechnology ONC
$304.30
price up icon 1.77%
Kapitalisierung:     |  Volumen (24h):